Minoryx Therapeutics

About:

Minoryx Therapeutics offers pharmacological chaperones, which are small molecule drugs used for the treatment of genetic diseases.

Website: http://www.minoryx.com

Top Investors: European Investment Bank, Centre for the Development of Industrial Technology (CDTI), Inveready, EASME - EU Executive Agency for SMEs, Kurma Partners

Description:

Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.

Total Funding Amount:

127M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Barcelona, Catalonia, Spain

Founded Date:

2011-01-01

Contact Email:

info(AT)minoryx.com

Founders:

Joan Aymamí, Marc Martinell, Xavier Barril

Number of Employees:

11-50

Last Funding Date:

2022-05-31

IPO Status:

Private

Industries:

© 2025 bioDAO.ai